Course catalogue doctoral education - VT24
-
Startpage
Ansökan kan ske mellan 2023-10-16 och 2023-11-15
Application closed
Print
| Title | Immunogenicity: Immune responses against biological drugs |
|---|---|
| Course number | 3067 |
| Programme | 1-Ingår i flera program |
| Language | English |
| Credits | 1.5 |
| Date | 2021-05-24 -- 2021-05-28 | Responsible KI department | Institutionen för klinisk neurovetenskap |
| Specific entry requirements | |
| Purpose of the course | Understanding of central terms and definitions in the field of immunogenicity, used in research and in clinical applications. To become familiar with the identified molecular and cellular immunological processes that trigger and increase the risk for developing anti-drug antibodies (ADA). Understanding of how immunogenicity needs to be taken into consideration all the way from choosing your biological target of treatment, to drug development, approval, clinical routine and individualized therapy and health care practice. |
| Intended learning outcomes | At the end of the course the student should be able to: - Understand what determines the immunogenicity of drugs and why they differ in this respect. - Give examples of different methods of how to measure drug level and ADA. - Understand the algorithms needed in clinical practice and what consequences ADA might have for treatment decision, safety and efficacy. - Integrate this knowledge in your own research project or a disease and treatment of choice. |
| Contents of the course | The course will give you an orientation of the clinical research fields where treatment with biopharmaceuticals are important and how the immune system can react against different biopharmaceuticals. It will include the diseases MS, RA, IBD, and SLE and biopharmaceuticals like IFNbeta, natalizumab, rituximab, TNF-blockers as well as the biosimilars for these. A range of immunoassay methodologies that can be used to measure drug levels and ADA will be presented and the clinical relevance of the test results discussed. The course will also give insights on the type of research being done to identify risk factors for ADA, and optimisation of drug design, production and administration to minimize the risk. Ways to improve treatment regiments adopted to results of drug level and ADA, as well how to monitor and store data in clinical routine will be discussed. |
| Teaching and learning activities | Lectures, individual essays, peer-review and oral presentation. |
| Compulsory elements | Lectures, essay, peer-review and oral presentation. Absence from lectures can be compensated for by writing an additional essay on the subject missed. |
| Examination | Essay, peer-review and oral presentation. |
| Literature and other teaching material | Articles selected by the teachers and by own literature search in PubMed or other data bases. |
| Number of students | 10 - 50 |
| Selection of students | Selection will be based on 1) the relevance of the course syllabus for the applicant's doctoral project (according to written motivation), 2) start date of doctoral studies (priority given to earlier start date) |
| More information | Depending on the pandemic situation, the course will be at CMM or online or both. This course is given jointly by the doctoral programmes Allergy, immunology and inflamation (Aii) and Neuroscience (Neuro). See: https://staff.ki.se/doctoral-programmes |
| Additional course leader | Nicky Dunn and Nastya Kharlamova are co-organizers. |
| Latest course evaluation | Course evaluation report |
| Course responsible |
Anna Fogdell-Hahn Institutionen för klinisk neurovetenskap Anna.Fogdell-Hahn@ki.se CMM Solna |
| Contact person | - |
